Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the ribonucleic acid (RNA)-dependent RNA polymerase of RNA viruses \[[@CR1]\]. In Japan, it is approved for use with novel influenza virus and is thought to be an effective drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) presents a complex pathology including inflammation, endothelial damage, thrombus formation, and acute respiratory failure \[[@CR2]--[@CR4]\] This syndrome requires complex treatment to reduce viral genome amounts, anti-inflammatory drugs, and anticoagulation. We attempted the cocktail treatment of favipiravir, steroid, and heparin for COVID-19. This study aimed to evaluate the effect of cocktail therapy for severe COVID-19.

This prospective, single-center study was conducted on all patients admitted to our hospital by transfer from other hospitals who required mechanical ventilation for severe COVID-19 between April 2 and 27, 2020. COVID-19 was diagnosed with real-time reverse transcriptase-polymerase chain reaction in approved laboratories from nasopharyngeal and throat swabs and with lung computed tomography. The treatment protocol was as follows: oral favipiravir (3600 mg on day 1, 1600 mg from day 2 to day 14), methylprednisolone (1000 mg for 3 days), and low molecular weight (2000 IU every 12 h) or unfractionated heparin (10,000--12,000 IU/day). Methylprednisolone administration was begun on the 5th day from initial favipiravir administration. Heparin and dexmedetomidine were administered after intubation and mechanical ventilation was started. Wilcoxon signed-rank tests were used to assess patients' changes in paired PaO~2~/FIO~2~ (P/F) ratio, IL-6, and presepsin. All statistical analyses were performed with JMP, Version 13.0.0 (SAS Institute Inc.).

Thirteen patients with COVID-19 requiring mechanical ventilation were admitted during the study period. The treatment protocol was completed without any clinically important change in 2 patients with bronchial asthma, one with rheumatoid arthritis (early-stage steroid administration) and one with bleeding complication (without heparin). Patient characteristics and initial laboratory data are summarized in Table [1](#Tab1){ref-type="table"}. Mean patient age was 63 (range, 46--80) years, and 69.0% were men. Only one patient required extracorporeal membrane oxygenation. Time from first symptom appearance to favipiravir administration was 8.7 (range, 4--13) days. One patient died due to disseminated intravascular coagulation (DIC) on admission that gradually progressed to multiple organ failure. Table 1Characteristics of 13 patients with COVID-19CharacteristicsValueAge, mean (SD), years63 (12)Male sex, No. (%)9 (69)Body weight, mean (SD), kg70 (21)Bronchial asthma No. (%)1 (8)Diabetes mellitus, No. (%)7 (54)Hypertension, No. (%)8 (62)Sleep apnea syndrome, No. (%)3 (23)APACHE II score, median \[IQR\]9 \[5, 13\]PaO~2~/FIO~2~ ratio at intubation, mean (SD)210 (73)D-dimer on admission, median \[IQR\], ng/mL1.3 \[1.0, 2.8\]CRP on admission, median \[IQR\], mg/dL11.9 \[4.6, 19.6\]PCT on admission, median \[IQR\], ng/mL0.21 \[0.09, 0.54\]Presepsin on admission, median \[IQR\], pg/mL440 \[302, 763\]IL-6 on admission, median \[IQR\], pg/mL77.5 \[35.7, 161.9\]Time from first symptom appearance, mean (SD), day Favipiravir8.7 (2.6) Heparin10.8 (3.9) Steroid13.2 (2.9) Dexmedetomidine10.7 (4.1) Intubation9.9 (3.3)ECMO, No. (%)1 (8)Ventilator days, median \[IQR\], days11 \[9, 12\]Outcome, No. (%) Survived12 (92) Dead1 (8)*SD* standard deviation, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *IQR* interquartile range, *PaO*~*2*~ arterial partial pressure of oxygen, *FIO*~*2*~ fraction of inspiratory oxygen, *CRP* C-reactive protein, *PCT* procalcitonin, *IL-6* interleukin-6, *ECMO* extracorporeal membrane oxygenationContinuous variables were reported as median \[interquartile range\] (IQR). Categorical variables were reported as numbers and percentages

The time course of the clinical laboratory data is shown in Fig. [1](#Fig1){ref-type="fig"}. Day 1 indicates the first day of favipiravir administration. The P/F ratio changed very little over the first 6 days and then gradually recovered. The interleukin-6 peaked on day 4 and decreased thereafter. Presepsin also peaked on day 3, remained about the same until day 6, and then decreased. Fig. 1Changes of value, PaO2/FIO2, interleukin-6, and persepsin concentration in patients of SARS-CoV-2 infection. The graphs present trends in the mean (SD) values of the PaO~2~/FIO~2~ (P/F) ratio and interleukin-6 (IL-6) and presepsin (PSP) concentrations. Day 1 was the first favipiravir administration day, and administration of steroid was begun in almost all patients on day 6. The P/F ratio on day 1 was significantly lower than that on days 8--11 (*P* \< .05). The IL-6 concentration peaked on day 4 and gradually decreased after that. The IL-6 on day 1 was significantly higher than that on days 7--12 (*P* \< .05). The PSP on day 1 was significantly lower than that on days 7 and 11 (*P* \< .05)

The clinical course of SARS-CoV-2 treatment with the cocktail in mechanically ventilated patients with COVID-19 indicated that favipiravir could partially control inflammatory mediators but could not completely control them or respiratory status. The respiratory distress of SARS-CoV-2 is thought to be due not only to direct viral action but also to chemical mediators induced by SARS-CoV-2. Inflammation and cytokine storm continued after favipiravir administration, and they could be controlled with steroid in our patients. Limitations of this study include its small sample size and performance in a single medical center. The start of favipiravir administration was delayed. Steroid therapy has adverse effects, and we did not assess long-term complications \[[@CR3]\]. Nevertheless, the results suggested that favipiravir was of some benefit, and the findings helped inform a treatment strategy for severe COVID-19.
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